Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck's commercial operations head Marie-Laure Pochon resigns

Cites 'family and private reasons'

Lundbeck Marie-Laure PochonLundbeck's executive vice president of commercial operations Marie-Laure Pochon has resigned after five years with the Danish pharma company.

She had only held the post of VP of commercial operations since last September and exits just three months after Lundbeck reorganised its European operations into two regional units.

"I have had a fantastic journey with Lundbeck and feel that the company now has a strong commercial platform with many product launches in the near-term future. However, for family and private reasons, I have made the decision to resign," she said.

Lundbeck has handed senior vice president Ole Chrintz responsibility for its European commercial operations, in addition to his current international role. 

He is already a member of Lundbeck's corporate management group and will report to CEO Ulf Wiinberg.

As part of the changes Andreas Eggert, vice president of global product strategy and portfolio development, and Staffan Schuberg, president of Lundbeck US, will also report directly to Wiinberg.

Pochon joined Lundbeck in 2007 and served as chief executive of Lundbeck France and regional vice president for France, Belgium, UK, Spain, Italy, Turkey and Germany.

"I respect Marie-Laure's decision and would like to thank her for her dedication and contribution to Lundbeck during the five years she has been with the company," said Wiinberg.

"We will continue the implementation of our commercial strategy to diversify our product portfolio and expand geographically with our strong and very capable commercial leadership team."

Pochon also sat on Lundbeck's executive management committee, which will now consist of just Wiinberg, chief financial officer Anders Götzsche and R&D head Anders Gersel Pedersen.

10th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics